Grants

W12-026: Anti-­immune evasive therapy in the treatment of FIP -­‐ a randomized, controlled clinical trial

Feline coronavirus exists in two forms: a less harmful (avirulent) strain that can cause mild enteritis and a highly pathogenic (virulent) strain that causes a progressive and usually fatal disease known as feline infectious peritonitis (FIP). Cats living in multi-­‐cat environments (e.g., shelter cats or cats in breeding catteries) are at a particularly high risk to develop FIP. An effective therapy is currently not available and affected cats usually succumb to their disease. Previous research has shown that FIP virus can evade the host’s immune system and that a specific blocking agent can inhibit this evasion mechanism. In this project, the investigators want to evaluate the efficacy of the inhibitor as a treatment for FIP in 10 naturally infected cats. The goal of this study is to improve the quality of life and survival of FIP affected cats by enabling the host’s immune system to recognize and destroy infected cells. (Bria Fund Study)

Grant ID: W12-026

Status: Active

Year Funded: 2012

Amount awarded: $24,962

Investigator: Prof. Dr. Hans Nauwynck; Sabine Gleich, DVM; Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Belgium